ACHP Statement on Final CY2026 MA and Part D Rule
ACHP President and CEO Ceci Connolly released a statement in response to CMS’ final CY2026 Medicare Advantage and Part D rule.
Tag: GLP-1s
ACHP Statement on 2027 Medicare Drug Negotiations
As the only national payer group to push for comprehensive drug reforms, ACHP believes that it is past time for pharmaceutical companies to answer for their pricing practices.
ACHP Statement on CY2026 Medicare Advantage and Part D Rate Notice
We are pleased that CMS is anticipating a new risk-adjustment model calibrated on MA encounter data, reflected in our MA for Tomorrow initiative.
